Kidney Stones Management Market Size By Type (Calcium Oxalate, Calcium Phosphate, Uric Acid, Struvite, Cysteine), By Diagnostics (Abdominal X-ray, Computed Tomography, Ultrasound, Abdominal MRI, Intravenous Pyelography), By Treatment (Extracorporeal Shock

Kidney Stones Management Market Size By Type (Calcium Oxalate, Calcium Phosphate, Uric Acid, Struvite, Cysteine), By Diagnostics (Abdominal X-ray, Computed Tomography, Ultrasound, Abdominal MRI, Intravenous Pyelography), By Treatment (Extracorporeal Shock Wave Lithotripsy {ESWL}, Ureteroscopy, Percutaneous Nephrolithotomy {PCNL}), COVID-19 Impact Analysis, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2022 - 2028

The kidney stones management market is estimated to register exponential growth by 2028 on account of rising awareness among people regarding overall kidney health. In addition, notable improvements in the ureteroscopy technique are set to boost market development over the forecast period.

Recent advancements in kidney stones management, including laser (Moses) technology, single-use ureteroscopes, and a miniaturized procedure called percutaneous nephrolithotomy (PCNL), have augmented industry uptake in recent years.

Moreover, to accommodate the escalating demand for services such as ureteroscopy, industry players have been engaging in profitable strategies, which has positively impacted the overall business outlook. For instance, in April 2019, Dornier Medtech, a leading urology company, launched its novel single-use flexible digital ureteroscope dubbed AXIS™ and other stone management products in the United States. The AXIS™ single-use flexible digital ureteroscope has been designed to eliminate the risk of cross-contamination between patients in the operating room.

In another instance, in September 2021, Boston Scientific, a global medical devices manufacturer, announced the acquisition of Lumenis LTD., a prominent surgical business specializing in fiber, laser systems, and accessories used for urology procedures. The deal enabled Boston Scientific to expand its laser portfolio in kidney stones management by leveraging Lumenis’ innovative MOSES™ technology.

The kidney stones management market has been segmented on the basis of treatment, type, diagnostics, and region. In terms of type, the market has been divided into cysteine, calcium oxalate, struvite, calcium phosphate, and uric acid. The calcium phosphate sub-segment is anticipated to grow at a significant CAGR over the review period to reach a valuation of around USD 177.6 million by the end of 2028.

From the diagnostics point of view, the kidney stones management market has been bifurcated into intravenous pyelography, abdominal X-ray, abdominal MRI, computed tomography, ultrasound, and others. In 2021, the abdominal MRI sub-segment was valued at nearly USD 230.2 million and is slated to expand at a robust pace over 2022-2028.

With respect to treatment, the market has been categorized into percutaneous nephrolithotomy PCNL), extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, and others. The ureteroscopy sub-segment accounted for more than 24.2% market share in 2021 and is set to progress at a considerable growth rate through the assessment period.

On the regional front, the Latin America kidney stones management industry accounted for a market share of about 5.8% in 2021 and is projected to gain substantial traction through the stipulated timeline. Meanwhile, the Middle East & Africa kidney stones management market is expected to witness steady growth at a CAGR of approximately 7.6% over the analysis period.